Recurrence after Surgery for Primary Hyperparathyroidism in 517 Patients with Multiple Endocrine Neoplasia Type 1. An AFCE and GTE study (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines).


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
03 Jul 2023
Historique:
medline: 30 6 2023
pubmed: 30 6 2023
entrez: 30 6 2023
Statut: aheadofprint

Résumé

To assess recurrence according to the type of surgery for primary hyperparathyroidism (pHPT) in MEN1 patients and to identify the risk factors for recurrence after initial surgery. In MEN 1 patients, pHPT is multiglandular and the optimal extent of initial parathyroid resection influences the risk of recurrence. MEN1 patients who underwent initial surgery for pHPT between 1990 and 2019 were included. Persistence and recurrence rates after less than subtotal (LTSP) and subtotal (STP) were analyzed. Patients with total parathyroidectomy (TP) with reimplantation were excluded. 517 patients underwent their first surgery for pHPT: 178 had LTSP (34.4%) and 339 STP (65.6%). The recurrence rate was significantly higher following LTSP (68.5%) than STP (45%) (P<0.001). The median time to recurrence after pHPT surgery was significantly shorter after LTSP than after STP: 4.25 (1.2-7.1) versus 7.2 (3.9-10.1) years (P<0.001). A mutation in exon 10 was an independent risk factor of recurrence after STP (Odds Ratio=2.19; 95% CI [1.31; 3.69] P=0.003). The five and ten-year recurrent pHPT probabilities were significantly higher in patients after LTSP with mutation in exon 10 (37% and 79% versus 30% and 61% P=0.016). Persistence, recurrence of pHPT and reoperation rate are significantly lower after STP than LTSP in MEN 1 patients. Genotype seems to be associated with recurrence of pHPT. A mutation in exon 10 is an independent risk factor for recurrence after STP and LTSP may not be recommended when exon 10 is mutated.

Sections du résumé

OBJECTIVE OBJECTIVE
To assess recurrence according to the type of surgery for primary hyperparathyroidism (pHPT) in MEN1 patients and to identify the risk factors for recurrence after initial surgery.
SUMMARY BACKGROUND DATA BACKGROUND
In MEN 1 patients, pHPT is multiglandular and the optimal extent of initial parathyroid resection influences the risk of recurrence.
METHODS METHODS
MEN1 patients who underwent initial surgery for pHPT between 1990 and 2019 were included. Persistence and recurrence rates after less than subtotal (LTSP) and subtotal (STP) were analyzed. Patients with total parathyroidectomy (TP) with reimplantation were excluded.
RESULTS RESULTS
517 patients underwent their first surgery for pHPT: 178 had LTSP (34.4%) and 339 STP (65.6%). The recurrence rate was significantly higher following LTSP (68.5%) than STP (45%) (P<0.001). The median time to recurrence after pHPT surgery was significantly shorter after LTSP than after STP: 4.25 (1.2-7.1) versus 7.2 (3.9-10.1) years (P<0.001). A mutation in exon 10 was an independent risk factor of recurrence after STP (Odds Ratio=2.19; 95% CI [1.31; 3.69] P=0.003). The five and ten-year recurrent pHPT probabilities were significantly higher in patients after LTSP with mutation in exon 10 (37% and 79% versus 30% and 61% P=0.016).
CONCLUSION CONCLUSIONS
Persistence, recurrence of pHPT and reoperation rate are significantly lower after STP than LTSP in MEN 1 patients. Genotype seems to be associated with recurrence of pHPT. A mutation in exon 10 is an independent risk factor for recurrence after STP and LTSP may not be recommended when exon 10 is mutated.

Identifiants

pubmed: 37389888
doi: 10.1097/SLA.0000000000005980
pii: 00000658-990000000-00533
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest.

Auteurs

Nicolas Santucci (N)

Department of Digestive and Endocrine Surgery, Dijon University Hospital, Dijon, France.
INSERM, U1231, EPICAD Team UMR "Lipids, Nutrition, Cancer", Dijon, France.

Elea Ksiazek (E)

INSERM, CIC1432, Clinical epidemiology Dijon, France.

François Pattou (F)

Department of General and Endocrine Surgery, University Hospital. Lille, INSERM U1190, Lille, France.

Gregory Baud (G)

Department of General and Endocrine Surgery, University Hospital. Lille, INSERM U1190, Lille, France.

Eric Mirallié (E)

Department of Oncological, Digestive and Endocrine Surgery (CCDE) Hôtel Dieu, CIC-IMAD, Nantes, France.

Samuel Frey (S)

Department of Oncological, Digestive and Endocrine Surgery (CCDE) Hôtel Dieu, CIC-IMAD, Nantes, France.

Christophe Trésallet (C)

Department of Digestive and Endocrine Surgery, Avicenne University Hospital, AP-HP Sorbonne Paris Nord University, France.

Frédéric Sébag (F)

Department of General Endocrine and Metabolic Surgery, Conception University Hospital, APHM, Aix Marseille University, Marseille, France.

Carole Guérin (C)

Department of General Endocrine and Metabolic Surgery, Conception University Hospital, APHM, Aix Marseille University, Marseille, France.

Muriel Mathonnet (M)

Department of Surgery, Dupuytren University Hospital of Limoges, Limoges, France.

Niki Christou (N)

Department of Surgery, Dupuytren University Hospital of Limoges, Limoges, France.

Gianluca Donatini (G)

Department of General and Endocrine Surgery, University Hospital of Poitiers, Poitiers, France.

Laurent Brunaud (L)

Department of Gastrointestinal, Metabolic, and Cancer Surgery (CVMC), University Hospital of Nancy (CHRU Nancy), INSERM NGERE U1256, University of Lorraine, Rue du Morvan, 54511 Vandoeuvre-les-Nancy, France.

Sébastien Gaujoux (S)

Department of Endocrine and Pancreatic Surgery, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.

Fabrice Ménégaux (F)

Department of Endocrine and Pancreatic Surgery, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.

Haythem Najah (H)

Department of Hepatobiliary Surgery, Bordeaux University Hospital, Bordeaux, France.

Christine Binquet (C)

INSERM, U1231, EPICAD Team UMR "Lipids, Nutrition, Cancer", Dijon, France.
INSERM, CIC1432, Clinical epidemiology Dijon, France.

Pierre Goudet (P)

Department of Digestive and Endocrine Surgery, Dijon University Hospital, Dijon, France.

Jean-Christophe Lifante (JC)

Department of Digestive and Endocrine Surgery, University Hospital of Lyon Sud and EA 7425 HESPER, Health Services and Performance Research, University Claude Bernard Lyon 1, Lyon, France.

Classifications MeSH